Opko and Pfizer announce positive results in late-stage trial of human growth hormone treatment

Opko Health Inc. shares OPK, +8.61% soared 21% in premarket trade Monday, while Pfizer Inc. shares PFE, +0.15% rose 0.6%, after the companies announced positive results in a late-stage trial of a human growth hormone treatment for children with growth hormone deficiency, or GHD.